Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Zynerba Pharma CS (NQ: ZYNE )

3.570 USD -0.010 (-0.28%)
Streaming Delayed Price Updated: 9:41 AM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 94,532
Open 3.600
Bid (Size) 3.560 (25)
Ask (Size) 3.570 (19)
Prev. Close 3.580
Today's Range 3.559 - 3.600
52wk Range 2.550 - 7.450
Shares Outstanding 13,561,373
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
From GlobeNewswire News Releases

Performance

YTD
+7.21%
+7.21%
1 Month
+7.21%
+7.21%
3 Month
N/A
N/A
6 Month
-4.29%
-4.29%
1 Year
-31.61%
-31.61%

More News

Read More
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
From GlobeNewswire News Releases
Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
From Business Wire News Releases
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
From GlobeNewswire News Releases
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc.
From Business Wire News Releases
Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th An
From GlobeNewswire News Releases
First Week of ZYNE March 19th Options Trading
Tags Stocks
From Market News Video
The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors
From Business Wire News Releases
New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Co
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.